Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
J Intern Med ; 267(3): 295-304, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19572922

ABSTRACT

OBJECTIVE: To identify, in a prospective study, how blood pressure levels at the age of twenty predict hypertension and cardiovascular remodelling 20 years later. METHODS: Twenty-year-old men with blood pressure (BP) elevation [systolic blood pressure (SBP) 140-160 and/or diastolic blood pressure (DBP) 85-95 mmHg; blood pressure elevation (BPE) group] or normal BP [SBP 110-130 and DBP 60-80 mmHg; normal controls (NC) group] entered the study in 1987. In 2007, follow-up was conducted including ambulatory BP, echocardiography, anthropometric and intima media thickness (IMT) measurements. RESULTS: Assessed with 24-h ambulatory BP, the prevalence of hypertension was 35/47 (74.5%) and 1/17 (5.9%) in the BPE and NC group at follow-up respectively. Twenty-four hour mean arterial pressure (MAP) increased from 86.6 (0.8) to 97.2 (1.2) (P < 0.0001), and from 83.1 (1.5) to 88.1 (1.2) mmHg (P < 0.01) from baseline to follow-up in the BPE and NC group respectively. At follow-up, left ventricular mass index (LVMI) was 122 (4) and 106 (4) g m(-1) in the BPE and NC group (unpaired t-test; P < 0.01) respectively, whilst IMT was 0.61 (0.01) and 0.57 (0.01) mm in the BPE and NC group (P < 0.05) respectively. In a logistic regression model, prevalence of hypertension was best explained by office MAP and 24-h DBP at baseline (R(2) 0.333; P < 0.05). A combined model of office MAP, body mass index and insulin levels at baseline explained 56% of LVMI at follow-up. CONCLUSIONS: BP elevation in young age predicts hypertension and adverse cardiovascular remodelling at the age of 40 years. Baseline office MAP is the best predictor of hypertension, 24-h MAP and LVMI.


Subject(s)
Blood Pressure/physiology , Hypertension/physiopathology , Adult , Anthropometry , Blood Pressure Monitoring, Ambulatory , Carotid Arteries/diagnostic imaging , Heart Ventricles/diagnostic imaging , Humans , Hypertension/epidemiology , Iceland/epidemiology , Lipids/blood , Logistic Models , Male , Prevalence , Prospective Studies , Tunica Media/diagnostic imaging , Ultrasonography , Ventricular Function, Left/physiology , Young Adult
2.
J Thromb Haemost ; 4(8): 1781-9, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16879221

ABSTRACT

BACKGROUND: Several proatherothrombotic conditions are associated with enhanced levels of circulating proinflammatory cytokines, which are believed to impair endothelial fibrinolytic capacity. OBJECTIVE: This study aims at investigating how tumor necrosis factor (TNF)-alpha regulates endothelial gene expression of the key fibrinolytic enzyme tissue-type plasminogen activator (t-PA). METHODS: Cultured human umbilical vein endothelial cells were pretreated with selective inhibitors of the three major inflammatory signaling pathways activated by TNF-alpha; the nuclear factor kappa-B (NF-kappaB), the p38 mitogen-activated protein kinase (p38 MAPK), and the c-jun N-terminal kinase (JNK) pathways. Following TNF-alpha stimulation, effects on t-PA gene expression were evaluated with real-time reverse transcriptase polymerase chain reaction and interactions of nuclear proteins with potential gene regulatory elements were studied with electrophoretic mobility shift assays. RESULTS: Approximately 50% suppression of t-PA gene expression was observed after prolonged stimulation with TNF-alpha (> or =24 h). The repression was shown to be preferentially dependent on NF-kappaB activation, but also on p38 MAPK signaling. Further, we provide evidence for a TNF-alpha induced binding of NF-kappaB to the recently described kappaB site in the t-PA gene and of cyclic adenosine monophosphate response element binding protein (CREB) to the t-PA CRE-like site. CONCLUSIONS: We conclude that TNF-alpha impairs fibrinolytic capacity in vascular endothelial cells by a NF-kappaB and p38 MAPK-dependent suppression of t-PA. This mechanism sheds a light on how inflammation contributes to the pathogenesis of cardiovascular diseases.


Subject(s)
Endothelium, Vascular/metabolism , Gene Expression Regulation , NF-kappa B/metabolism , Tissue Plasminogen Activator/biosynthesis , Tumor Necrosis Factor-alpha/physiology , p38 Mitogen-Activated Protein Kinases/metabolism , Binding Sites , Cardiovascular Diseases/metabolism , Cells, Cultured , Endothelium, Vascular/cytology , Fibrinolysis , Humans , Inflammation , Protein Structure, Tertiary , Signal Transduction , Tumor Necrosis Factor-alpha/metabolism , Umbilical Veins/cytology
3.
Hypertension ; 35(4): 1002-8, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10775576

ABSTRACT

We recently discovered that patients with essential hypertension have a markedly impaired capacity for stimulated release of tissue plasminogen activator (tPA) from vascular endothelium. This defect may reduce the chance of timely spontaneous thrombolysis in case of an atherothrombotic event. We now investigated whether increased intraluminal pressure as such may depress vascular tPA release or downregulate its gene expression. Segments of human umbilical veins were studied in a new computerized vascular perfusion model under steady laminar flow conditions for 3 or 6 hours. Paired segments were perfused at high or physiological intraluminal pressure (40 versus 20 mm Hg) under identical shear stress (10 dyne/cm(2)). Quantitative immunohistochemical evaluation of cellular tPA immunoreactivity was performed on paraffin-embedded 5-microm vascular sections. tPA mRNA in endothelial cells was quantified with reverse transcription real-time TaqMan polymerase chain reaction with GAPDH as endogenous control. Secretion of tPA into perfusion medium was evaluated with SDS-PAGE and Western blotting, followed by densitometric quantification. High-pressure perfusion downregulated tPA gene expression with a 38% decrease in tPA mRNA levels (P=0.01) compared with vessels perfused under normal intraluminal pressure. tPA release into the perfusion medium was markedly suppressed by high pressure (P<0.01 ANOVA). The intracellular storage pool of tPA was reduced after 6 but not 3 hours. Thus, elevated intraluminal pressure downregulates tPA gene and protein expression and inhibits its release from the endothelium independently of shear stress. The defective capacity for stimulated tPA release that we demonstrated in patients with essential hypertension might thus be an effect of the elevated intraluminal pressure per se.


Subject(s)
Tissue Plasminogen Activator/metabolism , Umbilical Veins/metabolism , Blood Pressure , Down-Regulation , Humans , Immunohistochemistry , Polymerase Chain Reaction , Stress, Mechanical , Tissue Plasminogen Activator/genetics , Umbilical Veins/pathology , Umbilical Veins/physiopathology
4.
J Thromb Haemost ; 2(11): 1960-8, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15550028

ABSTRACT

Free, biologically active tissue-type plasminogen activator (tPA) is the main initiator of intravascular fibrinolysis, but little is known about the regulation of active tPA on the organ level. The aim was to investigate if the local availability of active tPA on the organ level depends on the local release rate of tPA or the arterial input of tPA and plasminogen activator inhibitor type 1 (PAI-1). Also, we wanted to evaluate if plasma levels predict capacity for endothelial release of fibrinolytic proteins. Invasive perfused-forearm studies were performed in 96 healthy subjects. Local release rates of fibrinolytic proteins were assessed at baseline and during endothelial stimulation. Stimulation by methacholine and desmopressin induced a 6- and 12-fold increase in total tPA release rates, respectively. With increasing local release rates of tPA a gradually closer correlation emerged between the total tPA secretion and the forearm output of active tPA (from r = 0.102, ns to r = 0.85, P < 0.0001). Forearm availability of active tPA was not related to arterial input of either tPA or PAI-1. Release rates and plasma levels of tPA were not correlated. Baseline release rates of active tPA increased to noon. The major determinant for the local availability of active tPA is the capacity of the endothelium to release tPA rather than the arterial input of PAI-1 or tPA. Despite a molar excess of PAI-1, the majority of tPA released during stimulation does not undergo local inactivation. The capacity to release tPA locally cannot be predicted from its plasma concentration.


Subject(s)
Tissue Plasminogen Activator/metabolism , Adult , Brachial Artery , Circadian Rhythm , Endothelium, Vascular/metabolism , Fibrinolysis , Humans , Male , Plasminogen Activator Inhibitor 1/blood , Plasminogen Activator Inhibitor 1/metabolism , Tissue Plasminogen Activator/blood
5.
Thromb Haemost ; 85(5): 875-81, 2001 May.
Article in English | MEDLINE | ID: mdl-11372682

ABSTRACT

Extracellular nucleotides such as ATP and UTP are released by activation of platelets and ischemic tissue injury. The aim of the present study was to investigate whether ATP and UTP can induce acute tPA release from the vascular endothelium in vivo. Nine healthy subjects were studied in a perfused-forearm model during stepwise intraarterial infusions of ATP and UTP (10-200 nmol/min), and UTP during inhibition of prostanoid and NO synthesis by indomethacin and L-NMMA. ATP and UTP induced a similar and marked stimulation of forearm tPA release which increased 11- and 18-fold above baseline (p < or =0.01 for both) in conjunction with pronounced vasodilation. Neither the acute tPA release nor the vasodilation could be abrogated by NO and prostanoid synthesis inhibition. The similar effect of ATP and UTP suggests that P2Y rather than adenosine receptors mediate the response. Release of extracellular nucleotides in ischemic tissue may induce a pronounced activation of the endogenous fibrinolytic system.


Subject(s)
Adenosine Triphosphate/pharmacology , Endothelium, Vascular/drug effects , Tissue Plasminogen Activator/drug effects , Tissue Plasminogen Activator/metabolism , Uridine Diphosphate/pharmacology , Adenosine Triphosphate/administration & dosage , Adult , Dose-Response Relationship, Drug , Endothelium, Vascular/metabolism , Enzyme Inhibitors/administration & dosage , Enzyme Inhibitors/pharmacology , Female , Forearm/blood supply , Hemodynamics/drug effects , Humans , Indomethacin/administration & dosage , Indomethacin/pharmacology , Infusions, Intra-Arterial , Male , Middle Aged , Nitric Oxide Synthase/antagonists & inhibitors , Prostaglandin Antagonists/administration & dosage , Prostaglandin Antagonists/pharmacology , Uridine Diphosphate/administration & dosage , Vasodilation/drug effects , omega-N-Methylarginine/administration & dosage , omega-N-Methylarginine/pharmacology
7.
Blood Press ; 9(2-3): 126-31, 2000.
Article in English | MEDLINE | ID: mdl-10855736

ABSTRACT

Neuropeptide Y (NPY), noradrenaline (NA) and adenosine 5'-triphosphate (ATP) are important co-transmitters in the sympathetic nervous system, which has a central role in cardiovascular control. In order to evaluate if hypertension is associated with alterations in vascular responses to sympathetic co-transmitters we studied the effects of intra-arterial infusion of NPY, NA and ATP on forearm blood flow. Blood flow was measured by venous occlusion plethysmography in six hypertensive (mean arterial blood pressure (MAP) 113 +/- 4 mmHg) and six matched normotensive subjects (MAP 97 +/- 3 mmHg). NPY and NA significantly reduced forearm blood flow, while a powerful increase was seen with ATP. Forearm vascular resistance, calculated as MAP divided by forearm blood flow, was significantly increased by NPY and NA and strongly reduced by ATP. There was no difference between hypertensive and normotensive subjects in response to either transmitter. In conclusion, vascular reactivity to intra-arterial administration of NPY, NA and ATP seems to be intact in hypertensive patients without metabolic aberrations.


Subject(s)
Adenosine Triphosphate/pharmacology , Forearm/blood supply , Hypertension/physiopathology , Neuropeptide Y/pharmacology , Norepinephrine/pharmacology , Vasoconstrictor Agents/pharmacology , Humans , Injections, Intra-Arterial , Male , Middle Aged , Plethysmography/methods , Reference Values , Regional Blood Flow/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL